The Selection of Data Sources For Use in Modelling Studies
- 39 Downloads
Economic analysis has become increasingly important in healthcare in general, and particularly with respect to pharmaceuticals. Therefore, it is vital that the methods used in such evaluations are carefully scrutinised and refined. However, guidelines contain only a limited number of recommendations for the use of secondary data in modelling studies.
In this manuscript, the selection of data sources in modelling studies will be addressed. The objectives of this manuscript are as follows: (i) to present a general strategy on how to determine the appropriateness of a data source for a model; and (ii) to present recommendations on a transparent reporting format for the selection of data sources.
KeywordsAdis International Limited Treatment Failure Selective Serotonin Reuptake Inhibitor Healthcare Resource Generalise Anxiety Disorder
Unable to display preview. Download preview PDF.
- 1.Australia Commonwealth Department of Health, Housing and Community Services. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee. Canberra: Commonwealth Department, 1992Google Scholar
- 2.Commonwealth of Australia Department of Human Services and Health. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee including major submissions involving economic analysis. Canberra: Australian Government Publishing Service, 1995Google Scholar
- 3.Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals: Canada. 1st ed. Ottawa: CCOHTA, 1994Google Scholar
- 4.Ontario guidelines for economic analysis of pharmaceutical products. Ontario: Canadian Ministry of Health, Drug Programs Branch, 1993Google Scholar
- 5.Weinstein MC, Fineberg HV. Clinical decision analysis. Philadelphia: WB Saunders Co., 1980: 228–65Google Scholar
- 9.Jariath N, Weinstein J. The Delphi methodology (part 2): a useful administrative approach. Can J Nurs Adm 1994; 7 (4): 7–20Google Scholar
- 11.Barr J, Schumacher G. Using decision analysis to conduct pharmacoeconomic studies. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott—Raven Publishers, 1996: 1197–214Google Scholar
- 15.Clinical practice guideline. Depression in primary care: treatment of major depression (AHCPR publication no. 93-0551). Rockville (MD): Public Health Service, Agency for Health Care Policy and Research, 1993Google Scholar
- 17.Rote Liste 1993. Arzneimittelverzeichnis des BPI. Aulendorf/Würtemberg: Edition Cantor Verlag für Medizin und Naturwissenschaften GmbH, 1993Google Scholar
- 18.BMA. Bewertungsmass—stab für kassenärtzliche Leistungen. Cologne: Deutscher Artze—Verlag GmbH, 1993Google Scholar
- 19.DOK-8: AOK-Bundesverband 1994 Apr 15: 256Google Scholar